SYNTHEMA

The #HealthData4EU Cluster, which SYNTHEMA forms part of, will host the session “Ecosystems of Innovation in Healthcare: Ensuring Trust, Quality & Ethics in Data Use” at #EBDVF2025 in Copenhagen on 12–14 Nov

Event: european-big-data-value-forum.eu/2025-edition...
Cluster: synthema.eu/healthdata4eu/

Most synthetic data models assume data abundance. This study shows how transfer learning and meta-learning improve synthetic data generation for cancer research in low-data scenarios, where real clinical constraints apply.

👉 synthema.eu/publications/

#SYNTHEMA #SyntheticData #AI

Our partner i~HD is hosting a special 10th anniversary edition of its Annual Conference: “A Decade of Joining the Dots – Towards Bridging Data Spaces”

📍 3–4 Dec 2025 | Ghent, Belgium

Topics: EHDS, AI in healthcare, data quality, privacy & governance.

👉 www.i-hd.eu/ac2025

Most synthetic data models assume data abundance. This study shows how transfer learning and meta-learning improve synthetic data generation for cancer research in low-data scenarios, where real clinical constraints apply.

👉 synthema.eu/publications/

#SYNTHEMA #CancerResearch

Through collaborations with @radeep.bsky.social and ENROL, SYNTHEMA aligns rare disease datasets with European standards. This ensures interoperability across registries and hospitals, strengthening the foundation for synthetic data and AI solutions in real-world healthcare.

In #SYNTHEMA, data collection is central to building GDPR-compliant, AI-ready datasets for Sickle Cell Disease and Acute Myeloid Leukaemia. Harmonised across countries, the data supports synthetic generation, federated learning, and future rare disease research.

👉 synthema.eu/2025/09/23/d...

Data scarcity and fragmentation limit synthetic data in healthcare. This study introduces Synthetic Data Sharing, a federated learning method that improves representativeness and reduces disparities between data-rich and data-poor institutions.

👉 synthema.eu/publications/

#SYNTHEMA

Good data is not just collected, it is built with care. In #SYNTHEMA, clinical teams across Europe are creating high-quality, privacy-compliant datasets to power synthetic data and AI research in rare blood disorders.

👉Read more: synthema.eu/2025/09/23/d...

Cyber-physical systems need smarter tools for risk assessment. This study introduces an automated, simulation-based method aligned with ISO 27005. Validated through a real attack case and implemented in Spyderisk.

Read more 👉 synthema.eu/publications/

📰 The #BDVA Healthcare Task Force has published its white paper on Synthetic Data in Healthcare.

Proud to contribute alongside AISym4Med & SECURED, our sister projects in the #HEALTHDATA4EU cluster.

Read more 👉 bdva.eu/news/synthet...

#SyntheticData #SYNTHEMA

#SYNTHEMA is featured in The Innovation Platform (Issue 23), with an article on how synthetic data and federated AI are transforming research in rare blood disorders while keeping patient privacy at the core: www.innovationnewsnetwork.com/publication/...

#SyntheticData #RareDiseases

The #SYNTHEMA platform enables synthetic health data without moving sensitive patient info.
✔️ Data stays local
✔️ Federated learning across centres
✔️ FAIR-based quality & compliance

Tested in #SCD & #AML use cases. More info: synthema.eu

#SYNTHEMA is building the foundations for a future where synthetic, privacy-preserving data supports progress in rare diseases.

Beyond its two use cases, its flexible design can benefit other rare and underrepresented conditions.

More 👉 synthema.eu

Estimating treatment effects in healthcare is complex when data is decentralized and privacy is critical. This study applies federated learning to generative causal models for privacy-preserving ITE estimation across fragmented datasets.

👉 synthema.eu/publications/

#SYNTHEMA

Local data stays safe. Global research moves forward. With SYNTHEMA’s federated learning, hospitals never share patient data, but together they unlock new possibilities for rare disease research.

👉 synthema.eu

Sickle Cell Disease is a rare, life-threatening blood disorder with limited treatment options. In #SYNTHEMA’s Use Case 2, AI creates synthetic data from 1,000+ patients to study genetic factors & predict brain vascular events, while protecting privacy.

👉 synthema.eu/use-cases/

#AML is the most common acute leukemia in adults—fast-progressing but treatable. In SYNTHEMA’s Use Case 1, AI creates synthetic data from 2,500+ AML patients to predict survival & treatment responses, while protecting privacy.

Learn more about us: synthema.eu

Rare cancers make up over 20% of all cases but often lack tailored prognostic tools. The MOSAIC framework changes that, offering an AI-driven, privacy-preserving model for patient stratification and personalised risk assessment in myelodysplastic syndrome.

Read the article: synthema.eu/publications

✅ Secure Multi-Party Computation enables joint analysis without sharing private data. At #SYNTHEMA, it is key to building privacy-preserving health data solutions for rare hematological disease research, enabling collaboration without compromise.

👉 synthema.eu

What does it really mean for synthetic data to be private? This systematic review digs into 105 studies to map how privacy in SDG is defined, evaluated & applied, spotlighting differential privacy, GANs & healthcare use.

👉Read more: synthema.eu/publications/

#SYNTHEMA

As you might know, #SYNTHEMA is part of the HEALTHDATA4EU Cluster, 7 EU projects advancing secure, ethical health data use. Our joint white paper is coming soon, highlighting synthetic data, federated learning & cross-border collaboration.

👉 Learn more about our work: synthema.eu

Interested in synthetic data, rare diseases, or AI-powered breakthroughs in hematology? Visit SYNTHEMA’s publications section to explore work on data privacy, federated learning, AI in rare blood diseases, clinical decision-making for HSCT, and more.

👉Start reading: synthema-project.eu/publications

Differential Privacy (DP) adds smart noise to data, making it impossible to trace info back to individuals, without losing research value. At #SYNTHEMA, DP helps protect rare disease data while generating realistic, privacy-safe synthetic patients.

👉 synthema.eu

Last month, #SYNTHEMA and #GenoMed4All joined #EHA2025 in Milan to present our work on AI-powered federated platforms for data anonymisation & synthetic data. We also shared new insights on hydroxyurea treatment in SCD.

Read the recap: synthema.eu/2025/06/17/s...
#AIforHealth

Sickle Cell Disease is rare in the EU (fewer than 5 in 10,000 people), but its prevalence is rising across Europe due to migration and shifting demographics. #SYNTHEMA uses privacy-preserving AI and synthetic data to advance diagnosis, research & treatment.

👉 synthema.eu

At #EHA2025, Sigrid van der Veen (UMC Utrecht) presented a #SYNTHEMA-linked poster on hydroxyurea therapy in SCD.

Key findings on metabolites & personalised treatment 👉 library.ehaweb.org/eha/2025/eha...

#SickleCell #Genomed4All

We’re at #EHA2025! Visit us in Hall 4 and meet the #SYNTHEMA & #GenoMed4All teams.

📢 Don’t miss the Clinical and Data-Driven Research session by @erneurobloodnet.bsky.social tomorrow, 13:00–14:30, with our project experts!

👉 Agenda: lnkd.in/ejt_znV5

How can AI help protect privacy and advance rare disease research? Join #SYNTHEMA & #GenoMed4All at #EHA2025 for the Clinical & Data-Driven Research session by @erneurobloodnet.bsky.social.

🗓️ June 13 | 13:00–14:30
📍 Milan
👉 synthema.eu

#AIinHematolog

#SYNTHEMA collaborates with #RADeep, the EU-wide platform gathering data on rare anaemia disorders. With 200+ healthcare providers in 13+ countries, RADeep—under the @erneurobloodnet.bsky.social umbrella—bolsters our efforts to improve research and care.

👉Learn more about SYNTHEMA: synthema.eu

From registries to federated AI platforms, innovation in rare hematology takes the stage at #EHA2025.

Catch #SYNTHEMA & GENOMED4ALL on June 13 at the @erneurobloodnet.bsky.social Clinical and Data-Driven Research session in Milan.